News Centre Media Response Background Timetable Photo Gallery Webcast About Tianjin  Home  Chinese(GB)  
 
44.Bio-Pharmaceutical International Innovation Park is driving ahead the rapid development of Binhai New Area’s bio-industry
http://www.tj-summerdavos.cn    2008-09-19 11:53

In July of 2008, the Ministry of Science andTechnology and Tianjin Municipal Governmentstarted the construction of Jingjinji (Beijing-Tianjin-Hebei) Bio-Pharmaceutical IndustrializationDemonstration Area in joint effort. The areahighlights the Bio-Pharmaceutical InternationalInnovation Park, and develops the infrastructureand industry incubation platforms that are up tointernational standards.

With the start of the park’s construction, thebio-industry of Binhai New Area is embracing anera of rapid development.

In the period of “Eleventh Five-Year Plan”,China’s bio-industry has maintained rapid development.The 2007 output value of China’s biopharmaceuticalindustry totaled RMB 634 billionyuan with an increase of 25 percent year-onyear.The planting area in agriculture and forestryhas further increased and a number of newlyemergingindustries such as bio-energy, biomanufacturingand bio-service are taking shape.

Nevertheless, there is still a lot to be desired forChina’s bio-industry, compared to that of developedcountries. The local bio-enterprises aremore often of smaller scales and are in a comparativelystronger need to develop their capacityfor independent innovation. In terms of theproportion of the R&D input in the sales revenuein this industry, China only achieves one-tenthof that in developed countries.

In 2006, the Ministry of Science and Technology,the Ministry of Commerce, the Ministry ofHealth, the State Food and Drug Administrationand Tianjin Municipal Government decidedto establish Bio-Pharmaceutical InternationalInnovation Park in joint effort, making it an importantbio-technological and pharmaceuticalR&D transformation base to further drive thedevelopment and breakthrough in these twoindustries in China.

State-level Bio-Pharmaceutical International InnovationPark has a planned area of six squarekilometers, including R&D Zone, IncubationZone and Manufacturing and Commercial Zone.The core of R&D Zone is Tianjin InternationalBio-Pharmaceutical Joint Institute, which is alsothe symbol of the international innovation park.

Since 2006, the construction work on TianjinInternational Bio-Pharmaceutical Joint ResearchInstitute has been in full swing. A major buildingof 70,000 square meters, part of the first-stageconstruction, is supposed to be completed atthe end of this year. Other first-stage sharedtechnological platform projects include ClinicalTest Platform, Drug Analysis and Test Center andGLP Drug Safety Evaluation Center, all of whichwill be put into service in early 2009.

The research institute promotes cooperation ona world-wide scale. It is establishing Sino-ItalianTraditional Chinese Medicine Joint Laboratorywith Italian National Institute of Health, and ithas reached an agreement with Sweden’s KarolinskaInstitute to co-establish a R&D center.The Ministry of Science and Technology andTianjin municipal government also started injoint effort the construction of Jingjinji (Beijing-Tianjin-Hebei) Bio-Pharmaceutical IndustrializationDemonstration Area in the Binhai New Areawith a planned area of 10 square kilometers. Infive years, 100 major projects that push forwardthe transformation of pharmaceutical researchand development are supposed to be established,generating an industry scale totaling RMB50 billion yuan and making the Binhai New Areaa pharmaceutical R&D base with China’s ownintellectual property rights.

Presently, in order to expedite the developmentof the demonstration area, Tianjin has unveileda series of preferential policies to encouragepeople, institutes and enterprises to make innovationand start business. For instance, FundDevoted to Talent Pooling, which totals RMB200 million yuan annually, has been established.Those nominated entrepreneurs with their ownintellectual property rights and projects of industrializationprospect will be sponsored withspecialized fund of RMB 3 million yuan.

China’s Eleventh Five-Year Plan on Bio-Industryproposes that bio-industry should become anewly-emerging industry that develops fast, hasa good quality efficiency and far-reaching andinfluential impact on other industries. Accordingto the plan, till the year of 2010, the output valueof bio-industry in China will have reached morethan RMB 500 billion yuan, accounting for twopercent of the year’s GDP.


From:Enorth.com.cn    Editor: Zhao Jing
 
Preparatory & Coordination Committee of Annual Meeting of the New Champions 2008